Recombinant factor VIIa: hemostatic adjunct in the coagulopathic burn patient

Area of Science:

• Burn injury management
• Hemostasis and thrombosis
• Pharmacological interventions

Background:

• Recombinant factor VIIa (rFVIIa) is established for hemophilia management.
• Severe coagulopathy presents a significant challenge in burn patient care.

Purpose of the Study:

• To report the successful application of rFVIIa in a burn patient experiencing severe coagulopathy.
• To evaluate the hemostatic efficacy of rFVIIa in a non-hemophilic coagulopathic context.

Main Methods:

• A 63-year-old male burn patient (60% total body surface area) developed generalized coagulopathy.
• Treatment involved extensive surgical procedures, allograft placement, and subsequent autografting.
• rFVIIa was administered due to persistent bleeding and hemodynamic instability despite blood product transfusion.

Main Results:

• Hemodynamic stability was achieved within 4 hours of rFVIIa administration.
• Serial hematocrit measurements remained stable post-treatment.
• Hemostasis was successfully achieved, attributed to rFVIIa combined with platelet therapy.

Conclusions:

• rFVIIa can be successfully employed to manage severe coagulopathy in burn patients.
• This case expands the known applications of rFVIIa in critical care settings.